Penn
Medicine Lancaster General Health
Brings Advanced Cancer Treatment to Lancaster
Advanced CAR T-cell immunotherapy is now available at the Ann B.
Barshinger Cancer Institute
LANCASTER, PA – Penn Medicine Lancaster General Health’s Ann B. Barshinger
Cancer Institute now offers the advanced cancer treatment CAR T-cell
immunotherapy, a groundbreaking immunotherapy treatment that was developed at
Penn Medicine in Philadelphia.
CAR T (Chimeric Antigen Receptor T-Cell) is a type of cancer
therapy that uses specially modified immune cells from a patient’s own body.
T-cells, a type of white blood cell, are removed from the patient and
reprogrammed to find and attack cancer cells when reinfused into the
bloodstream.
Penn Medicine is a global leader in immunotherapy research
that expands the safety and effectiveness of CAR T. CAR T was the first gene
therapy to be approved by the Food and Drug Administration (FDA) and has
brought a new era of cancer treatment options.
CAR T-cell therapy is used to treat patients with certain
kinds of aggressive blood cancers that have not responded to one or more
therapies, such as large B-cell lymphoma, the most common type of non-Hodgkin
lymphoma.
For more information on CAR T-cell therapy, please visit our
website lghealth.org.
